Gene · 113451
Papers1,387
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,387
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CRISPR-Cas9 mediated adiA knockout in Hafnia paralvei: Implications for agmatine production and acid stress survival in a fermented dairy matrix. | Food Microbiol | 2027 | 42668207 | PubTator, text mining | PubMed |
| Tumor-associated calcium signal transducer 2 expression as a promising therapeutic target in esophageal squamous cell carcinoma: a combined the Cancer Genome Atlas and an institutional cohort. | Esophagus | 2026 | 42763384 | PubTator, text mining | PubMed |
| Letter to the Editor: ADC as a non-invasive surrogate for PD-L1 in cervical cancer-addressing potential confounding and the leap to immunotherapy selection. | Eur Radiol | 2026 | 42758291 | PubTator, text mining | PubMed |
| Reply to the Letter to the Editor: ADC as a non-invasive surrogate for PD-L1 in cervical cancer-addressing potential confounding and the leap to immunotherapy selection. | Eur Radiol | 2026 | 42758286 | PubTator, text mining | PubMed |
| From ICI resistance to therapeutic vulnerability: A resistance-state framework for appraising antibody-drug conjugate evidence in solid tumors. | Crit Rev Oncol Hematol | 2026 | 42754126 | PubTator, text mining | PubMed |
| A framework for evaluating unexpected reactions in antibody-drug conjugates during clinical development: a case study of a promiscuous payload. | MAbs | 2026 | 42745381 | PubTator, text mining | PubMed |
| CD97/ADGRE5 in Cancer: Structural Activation, Context-Dependent Signaling, and Therapeutic Targeting. | Cells | 2026 | 42738898 | PubTator, text mining | PubMed |
| Integrated Analysis of HER2 Expression and ERBB2 Alterations in Bladder Cancer. | Cancer Sci | 2026 | 42732768 | PubTator, text mining | PubMed |
| Anti-HER2 therapy-associated echocardiography-related cardiac dysfunction and severe outcomes: Comparison of disproportionality and report-level cluster analyses. | Br J Clin Pharmacol | 2026 | 42705876 | PubTator, text mining | PubMed |
| Spatially Driven DNA-Based Probe Proximity Assay for Total Antibody Quantification in Antibody-Drug Conjugates. | ACS Sens | 2026 | 42687273 | PubTator, text mining | PubMed |
| Coordinated Expression of ADC Targets ERBB2, TACSTD2, and NECTIN4 in Bladder Cancer: A Multi-Scale Transcriptomic and Proteomic Landscape Analysis. | Curr Issues Mol Biol | 2026 | 42651823 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates in Contemporary Oncology: A Clinical Perspective on Dose Optimization, Sequencing, and Combination Strategies. | Cancers (Basel) | 2026 | 42649965 | PubTator, text mining | PubMed |
| Mechanistic Analysis of Drug Linker Clearance During Ultrafiltration/Diafiltration of an Antibody-Drug Conjugate. | Biotechnol Bioeng | 2026 | 42629990 | PubTator, text mining | PubMed |
| Antibody-drug conjugate development in lymphoma: a systematic clinical trial landscape analysis. | Front Immunol | 2026 | 42620849 | PubTator, text mining | PubMed |
| Comparative safety profiles of antibody-drug conjugates: a real-world analysis of monotherapy and combination regimens in solid tumors. | Drug Deliv | 2026 | 42557654 | PubTator, text mining | PubMed |
| A mouse PDX clinical trial reveals broad efficacy of niraparib and vc-seco-DUBA anti-HER2 ADC SYD985 in HER2/neu expressing endometrial cancer. | Biomed Pharmacother | 2026 | 42551191 | PubTator, text mining | PubMed |
| Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis. | Front Oncol | 2026 | 42534809 | PubTator, text mining | PubMed |
| ADC Conjugation Strategies: From Technological Evolution to a Practical Selection Framework. | Pharmaceutics | 2026 | 42514930 | PubTator, text mining | PubMed |
| The expression landscape and heterogeneity of nectin-4, HER2, and Trop-2 in urothelial carcinoma: clinicopathological correlations and implications for ADC-guided precision therapy. | Front Oncol | 2026 | 42488113 | PubTator, text mining | PubMed |
| Interstitial lung disease in patients treated with antibody-drug conjugates: a review. | Lung Cancer | 2026 | 42462539 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/113451/papers